Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3066-3071

  Crump, Michael ^a   Tu, Dongsheng ^a   Shepherd, Lois ^a   Levine, Mark ^a   Bramwell, Vivien ^a   Pritchard, Kathleen ^a  

^a Queen's Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT; CEF REGIMEN; CISPLATIN; CMF PROTOCOL; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ACUTE DISEASE; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; LEUKEMIA; MIDDLE AGED; MULTIPLE CANCER; RISK;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUKEMIA; METHOTREXATE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; RISK;

EID: 0042914714     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.137     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
2. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
3. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared to cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
4. Findlay B, Tonkin K, Crump M, et al: A dose escalation trial of adjuvant CEF chemotherapy with G-CSF for premenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 15:99, 1996
5. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003
6. Smith MA, Rubinstein L, Cazenave L, et al: Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 85:554-558, 1993
7. Pepe MS, Mon M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737-751, 1993
8. Pepe MS: Inference for events with dependent risks in multiple endpoint studies. J Am Stat Assoc 86:770-778, 1991
9. Andersen MK, Christiansen DH, Jensen BA, et al: Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. Br J Haematol 114:539-543, 2001
10. French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6:679-688, 1988
11. Diamandidou E, Buzdar AU, Smith TL, et al: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 14:2722-2730, 1996
12. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 21:1195-1204, 2003
13. Pedersen-Bjergaard J, Rowley JD: The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83:2780-2786, 1994
14. Fisher B, Rockette H, Fisher ER, et al: Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J Clin Oncol 3:1640-1658, 1985
15. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol 13:1557-1563, 1995
16. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5:803-808, 1994
17. Chaplain G, Milan C, Sgro C, et al: Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study. J Clin Oncol 18:2836-2842, 2000
18. Linassier C, Barin C, Calais G, et al: Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 11:1289-1294, 2000
19. Seeker-Walker LM, Moorman AV, Bain BJ, et al: Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities: EU Concerted Action 11q23 Workshop. Leukemia 12:840-844, 1998
20. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5- year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001
21. Piccart MJ, Di Leo A, Beauduin M, et al: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19:3103-3110, 2001
22. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high- risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384-1391, 2000
23. Fisher B, Andersen S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
24. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
25. Curtis RE, Boice JD, Jr., Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751, 1992
26. Felix CA, Walker AH, Lange BJ, et al: Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95: 13176-13181, 1998
27. Allan JM, Wild CP, Rollinson S, et al: Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 98:11592-11597, 2001
28. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial c9741/ cancer and leukemia group B trial 9741. J Clin Oncol 21:1431-1439, 2003
29. Mamounas EP: Evaluating the use of paclitaxel following doxorubicin/ cyclophosphamide in patients with breast cancer and positive axillary nodes. Adjuvant Therapy for Breast Cancer: NIH Consensus Development Conference, Bethesda, MD, National Institutes of Health, Nov 1- 3, 2000, 2002